Diagnostic Techniques: Autofluorescence

Midena, Edoardo; Frizziero, Luisa; Pilotto, Elisabetta; Parrozzani, Raffaele

doi:10.1007/978-3-030-04489-3_21

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite being able to distinguish lesions from normal tissue, the low penetration capability of OCT limits its usage to only very thin lesions, typically less than 1 mm in thickness, especially in melanocytic lesions [ 11 ], whereas choroidal tumors can have a height of up to 10 mm [ 12 ]. Imaging techniques such as fluorescein angiography (FA), indocyanine green angiography (ICGA), and fundus autofluorescence (FAF) can provide valuable information such as changes in the retinal pigmented epithelium (RPE) overlying ocular lesions, tumor vasculature, and associated vascular leakage [ 1 , 2 , 13 , 14 ]. However, these imaging modalities do not provide sufficient information related to tumor depth, and their standalone diagnostic accuracy is relatively low.…”

Section: Introductionmentioning

confidence: 99%

Integrating a Fundus Camera with High-Frequency Ultrasound for Precise Ocular Lesion Assessment

Rossi,

Zeng,

Rahimi

et al. 2024

Biosensors

View full text Add to dashboard Cite

Ultrasound A-scan is an important tool for quantitative assessment of ocular lesions. However, its usability is limited by the difficulty of accurately localizing the ultrasound probe to a lesion of interest. In this study, a transparent LiNbO3 single crystal ultrasound transducer was fabricated, and integrated with a widefield fundus camera to guide the ultrasound local position. The electrical impedance, phase spectrum, pulse-echo performance, and optical transmission spectrum of the ultrasound transducer were validated. The novel fundus camera-guided ultrasound probe was tested for in vivo measurement of rat eyes. Anterior and posterior segments of the rat eye could be unambiguously differentiated with the fundus photography-guided ultrasound measurement. A model eye was also used to verify the imaging performance of the prototype device in the human eye. The prototype shows the potential of being used in the clinic to accurately measure the thickness and echogenicity of ocular lesions in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Integrating a Fundus Camera with High-Frequency Ultrasound for Precise Ocular Lesion Assessment

Rossi,

Zeng,

Rahimi

et al. 2024

Biosensors

View full text Add to dashboard Cite

show abstract

“…Adjuvant topical chemotherapeutic agents are commonly applied to reduce recurrence rates or in cases where histopathological examination reveals incomplete excision. These include mitomycin C (MMC) 0.02 – 0.04%, 5-fluorouracil (5-FU) 1%, and interferon-alpha 2b (IFN- α 2b) 1 million IU/mL 6 . IFN- α 2b is often favoured, as it causes mild transient or no side effects at all, is well tolerated by patients, has a better safety profile, and appears to be as effective as MMC or 5-FU 7 , 8 .…”

Section: Introductionmentioning

confidence: 99%

Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: A Survey of Tertiary Eye Centres in Germany

Jiang

Böhringer

Auw-Hädrich

et al. 2023

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Purpose: To evaluate the standard of care, in particular the use of topical or subconjunctival Interferon-α2b, in treating ocular surface squamous neoplasia or melanocytic tumors among tertiary eye centers in Germany. Methods: A survey containing 14 questions was sent to 43 tertiary eye centers in Germany. The questions addressed the surgical and medical management of ocular surface squamous neoplasia and melanocytic tumors (primary acquired melanosis and malignant melanoma) as well as the clinical experiences and difficulties in prescribing off-label Interferon-α2b eye drops and subconjunctival injections. Results: Twenty-four tertiary eye centers responded to the survey. Eighty-three percent of centers have used Interferon-α2b in their clinical practice and 25% prescribed it as the first-line cytostatic agent following surgical excision of ocular surface squamous neoplasia, while 10% would do so for melanocytic tumors. Correspondingly, the majority of respondents selected Mitomycin C as their first-line agent. Side effects were uncommon with topical Interferon-α2b eye drops, but were more frequently reported after subconjunctival Interferon-α2b injections. In total, eight centers had experience with Interferon-α2b injections. The most significant obstacles perceived by ophthalmologists when prescribing Interferon-α2b were its high cost and the reimbursement thereof. Conclusion: Off-label Mitomycin C was the preferred adjuvant therapy for epithelial and melanocytic tumors, with Interferon-α2b being the standard second-line option. Interferon-α2b has predominantly been used to treat ocular surface squamous neoplasia and, to a lesser extent, melanocytic tumors at German tertiary eye centers. Following its market withdrawal, supply shortages of Interferon-α2b are likely to have a profound impact on patient care and their quality of life. Ziel: Evaluation des Therapiestandards, insbesondere der Verwendung von topischem oder subkonjunktivalem Interferon-α2b, bei der Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche oder melanozytären Tumoren der Augenoberfläche in tertiären Augenzentren in Deutschland. Methoden: Eine Umfrage mit 14 Fragen wurde an 43 tertiäre Augenzentren in Deutschland verschickt. Die Fragen befassten sich mit der chirurgischen und medizinischen Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche und melanozytären Tumoren (primär erworbene Melanose und malignes Melanom) sowie den klinischen Erfahrungen und Schwierigkeiten bei der Verschreibung von Off-Label Interferon-α2b Augentropfen und subkonjunktivalen Injektionen. Ergebnisse: 24 tertiäre Augenzentren nahmen an der Umfrage teil. 83% der Zentren hatten Interferon-α2b eingesetzt und 25 % verschrieben es als First-Line-Therapie nach chirurgischer Entfernung von Neoplasien der plattenepithelialen, okulären Oberfläche, wohingegen 10 % dies bei melanozytären Tumoren angewendet hätten. Dementsprechend wählte die Mehrheit der Befragten Mitomycin C als Mittel der ersten Wahl aus. Nebenwirkungen waren bei topischen Interferon-α2b Augentropfen selten, wurden aber häufiger nach subkonjunktivalen Interferon-α2b-Injektionen gemeldet. Insgesamt hatten acht Zentren Erfahrungen mit Interferon-α2b-Injektionen. Die größten Hürden, die Augenärzte bei der Verschreibung von Interferon-α2b hinderten waren die hohen Kosten und deren Übernahme durch die Krankenkassen. Schlussfolgerung: Off-label Mitomycin C war die bevorzugte adjuvante Therapie für epitheliale und melanozytäre Tumoren, während Interferon-α2b Standardoption für eine Zweitlinientherapie war. Interferon-α2b wurde in deutschen, tertiären Augenzentren vorwiegend zur Behandlung von Neoplasien der plattenepithelialen, okulären Oberfläche und in geringerem Maße von melanozytären Tumoren eingesetzt. Nach der Marktrücknahme von Interferon-α2b werden Lieferengpässe wahrscheinlich beträchtliche Auswirkungen auf die Patientenversorgung und ihre Lebensqualität haben.

show abstract

Diagnostic Techniques: Autofluorescence

Cited by 2 publications

References 26 publications

Integrating a Fundus Camera with High-Frequency Ultrasound for Precise Ocular Lesion Assessment

Integrating a Fundus Camera with High-Frequency Ultrasound for Precise Ocular Lesion Assessment

Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: A Survey of Tertiary Eye Centres in Germany

Contact Info

Product

Resources

About